PMID- 16415705
OWN - NLM
STAT- MEDLINE
DCOM- 20070403
LR  - 20221207
IS  - 0271-0749 (Print)
IS  - 0271-0749 (Linking)
VI  - 26
IP  - 1
DP  - 2006 Feb
TI  - Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, 
      fixed-dose, open-label trial.
PG  - 45-9
AB  - The purpose of our study was to evaluate the efficacy and tolerability of 
      low-dose olanzapine augmentation in selective serotonin reuptake inhibitor 
      (SSRI)-resistant panic disorder (PD) with or without agoraphobia. In this 
      12-week, open-label study, 31 adult outpatients with treatment-resistant PD who 
      had previously failed to respond to SSRI treatment were treated with fixed dose 
      of olanzapine (5 mg/d) in addition to SSRI. Efficacy was assessed using the Panic 
      Attack and Anticipatory Anxiety Scale (PAAAS), the Agoraphobic Cognitions 
      Questionnaire (ACQ), the Hamilton Rating Scale for Anxiety (HAM-A), the Hamilton 
      Rating Scale for Depression (HAM-D), the Global Assessment of Functioning Scale 
      (GAF), and the Clinical Global Impression of Improvement (CGI-I). Twenty-six 
      patients completed the trial period with a dropout rate of 16.1%. At week 12, 21 
      patients were responders (81.8%), and an overall improvement on all rating scales 
      was observed in all patients both with or without agoraphobia. Fifteen patients 
      (57.7%) achieved remission. Olanzapine was well tolerated and the most frequent 
      adverse effects were mild-to-moderate weight gain and drowsiness. No 
      extrapyramidal symptoms were reported. Olanzapine appears to be effective as 
      augmentation strategy in the treatment of SSRI-resistant PD, but study 
      limitations must be considered and placebo-controlled studies are needed.
FAU - Sepede, Gianna
AU  - Sepede G
AD  - Department of Oncology and Neurosciences, Institute of Psychiatry, University G. 
      D Annunzio of Chieti, Italy.
FAU - De Berardis, Domenico
AU  - De Berardis D
FAU - Gambi, Francesco
AU  - Gambi F
FAU - Campanella, Daniela
AU  - Campanella D
FAU - La Rovere, Raffaella
AU  - La Rovere R
FAU - D'Amico, Michele
AU  - D'Amico M
FAU - Cicconetti, Alessandra
AU  - Cicconetti A
FAU - Penna, Laura
AU  - Penna L
FAU - Peca, Silvana
AU  - Peca S
FAU - Carano, Alessandro
AU  - Carano A
FAU - Mancini, Enrico
AU  - Mancini E
FAU - Salerno, Rosa Maria
AU  - Salerno RM
FAU - Ferro, Filippo Maria
AU  - Ferro FM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Clin Psychopharmacol
JT  - Journal of clinical psychopharmacology
JID - 8109496
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 41VRH5220H (Paroxetine)
RN  - N7U69T4SZR (Olanzapine)
RN  - QUC7NX6WMB (Sertraline)
SB  - IM
MH  - Adult
MH  - Agoraphobia/complications/drug therapy
MH  - Antipsychotic Agents/*therapeutic use
MH  - Benzodiazepines/therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Olanzapine
MH  - Panic Disorder/complications/*drug therapy
MH  - Paroxetine/therapeutic use
MH  - Psychiatric Status Rating Scales
MH  - Selective Serotonin Reuptake Inhibitors/therapeutic use
MH  - Sertraline/therapeutic use
MH  - Treatment Failure
EDAT- 2006/01/18 09:00
MHDA- 2007/04/04 09:00
CRDT- 2006/01/18 09:00
PHST- 2006/01/18 09:00 [pubmed]
PHST- 2007/04/04 09:00 [medline]
PHST- 2006/01/18 09:00 [entrez]
AID - 00004714-200602000-00010 [pii]
AID - 10.1097/01.jcp.0000195108.01898.17 [doi]
PST - ppublish
SO  - J Clin Psychopharmacol. 2006 Feb;26(1):45-9. doi: 
      10.1097/01.jcp.0000195108.01898.17.